迪哲医药：肺癌领域多项最新研究成果在2025年世界肺癌大会(WCLC)上公布

Core Insights - The company reported on its new targeted lung cancer drug, Shuwozhe (generic name: Shuwotini tablets), and the highly selective JAK1 inhibitor, Gaoruizhe (generic name: Goliqixitini capsules), at the 2025 World Lung Cancer Conference (WCLC) [1][2] - The latest results from the international multicenter registration clinical study "WUKONG1B" for Shuwozhe showed a favorable benefit/risk ratio for treating EGFR Exon20ins NSCLC, with significant and durable anti-tumor efficacy and manageable safety [1] - Shuwozhe received priority review approval in the U.S. in July 2025, making it the only approved oral small molecule targeted therapy for EGFR Exon20ins NSCLC globally [1] Group 1 - The company presented 11 new studies related to non-small cell lung cancer (NSCLC) at WCLC [1] - The "WUKONG1B" study results were reported orally at the conference [1] - The ongoing research for Gaoruizhe in NSCLC treatment shows no dose-limiting toxicities (DLT) observed during the dose escalation phase [2] Group 2 - The research for Gaoruizhe is still ongoing with patient enrollment and data collection, which will provide important evidence for its clinical application in NSCLC [2]